Atorvastatin hemicalcium salt

SKU: orb1304521

Description

Atorvastatin Calcium is the hemicalcium salt form of Atorvastatin, an orally active HMG-CoA reductase inhibitor. It is widely used in research to study cholesterol-lowering mechanisms, employing both in vitro enzymatic assays and in vivo models of hyperlipidemia and atherosclerosis.

Research Area

Cell Biology, Metabolism Research

Key Properties

• CAS Number: 134523-03-8
• MW: 577.67
• Purity: 99.27%
• Formula: C₃₃H₃₄FN₂O₅·1/2Ca
• SMILES: CC(c1n(CCC(CC(CC([O-])=O)O)O)c(c2ccc(F)cc2)c(c3ccccc3)c1C(Nc4ccccc4)=O)C.CC(c5n(CCC(CC(CC([O-])=O)O)O)c(c6ccc(F)cc6)c(c7ccccc7)c5C(Nc8ccccc8)=O)C.[Ca+2]
• Target: Autophagy,HMG-CoA Reductase,Ferroptosis
• Solubility: DMSO:122.5 mg/mL (212.06 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:4 mg/mL (6.92 mM)

Bioactivity

• Target IC50:
  HMG-CoA reductase:8 nM|A549 cells:8.7 μM|SV-SMC (human) proliferation:0.39 μM|MKN45 cells:2.1 µM
• In Vivo:
  METHODS: To assay antitumor activity in vivo, CX5461 (50 mg/kg, 50 mmol/L NaH2PO4 pH 4.5) was administered orally to mice bearing MIA PaCa-2 or A375 xenografts once daily or every three days for 32 days. RESULTS: CX5461 showed a significant MIA PaCa-2 TGI equal to 69% on day 31. Similarly, CX5461 showed a significant A375 TGI with a TGI of 79% on day 32.
• In Vitro:
  METHODS: HCT-116, A375, MIA PaCa-2 and BJ hTERT cells were treated with CX5461 (0-10 µM) for 96 h and cell viability was measured by CyQUANT assay. RESULTS: Antiproliferative dose-response assessment of HCT-116, A375, and MIA PaCa-2 cell lines yielded EC50s of 167, 58, and 74 nmol/L, respectively. the EC50 of the BJ-hERT normal cell line was approximately 5000 nmol/L. METHODS: CaSki cells were treated with CX5461 (1-5 µM) for 24-72 h, and the expression levels of target proteins were detected by Western Blot. RESULTS: After CX5461 treatment, LC3I was completely converted to LC3II, while p62 expression was reduced. densitometric analysis of LC3I and LC3II bands showed that the LC3II:LC3I ratio was significantly increased after 72 h of CX5461 treatment.
• Cell Research:
  Briefly, SV-SMC from 5 different patients are seeded into 24-well cell culture plates at a density of 1×104 cells per well in full growth medium. Cells are incubated overnight and then quiesced in serum free medium for 3 days before transfer to full growth medium (10% FCS) containing 5 different statins (simvastatin, atorvastatin, fluvastatin, lovastatin, and pravastatin)at a range of concentrations. All statins are tested on cells from each individual patient. Medium and drugs are replaced after 2 days, and viable cell numbers are determined in triplicate wells after 4 days using Trypan Blue and a hemocytometer. The increase in cell number is calculated by subtracting the starting cell number (day 0) from the final cell number (day 4). Data are then normalized to control values (no statin) to correct for differences in proliferation rates between cells from different patients.

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

CI 981, CI981, CI-981, Autophagy, Atorvastatin Calcium, Atorvastatin hemicalcium, Atorvastatin hemicalcium salt, Atorvastatin, Lipitor, Ferroptosis, HMGCoAReductase, HMGCR, HMG-CoA reductase, HMGCoA Reductase, Sortis

Compound Identifiers

PubChem CID

21862717